Aldemir Mehmet Naci, Turkeli Mehmet, Simsek Melih, Yildirim Nilgun, Bilen Yusuf, Yetimoglu Harun, Bilici Mehmet, Tekin Salim Basol
Department of Medical Oncology, Faculty of Medicine, Ataturk University , Erzurum, Turkey E-mail :
Asian Pac J Cancer Prev. 2015;16(14):5933-7. doi: 10.7314/apjcp.2015.16.14.5933.
We aimed to investigate the prognostic value of baseline neutrophil, lymphocyte, and platelet counts along with the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in local and advanced gastric cancer patients.
In this retrospective cross-sectional study, a total of 103 patients with gastric cancer were included. For all, patient characteristics and overall survival (OS) times were evaluated. Data from a complete blood count test including neutrophil, lymphocyte, monocyte, white blood cell (WBC) and platelet (Plt) count, hemoglobin level (Hb) were recorded, and the NLR and PLR were obtained for every patient prior to pathological diagnosis before any treatment was applied.
Of the patients, 53 had local disease, underwent surgery and were administered adjuvant chemoradiotherapy where indicated. The remaining 50 had advanced disease and only received chemotherapy. OS time was 71.6±6 months in local gastric cancer patients group and 15±2 months in the advanced gastric cancer group. Univariate analysis demonstrated that only high platelet count (p=0.013) was associated with better OS in the local gastric cancer patients. In contrast, both low NLR (p=0.029) and low PLR (p=0.012) were associated with better OS in advanced gastric cancer patients.
This study demonstrated that NLR and PLR had no effect on prognosis in patients with local gastric cancer who underwent surgery and received adjuvant chemoradiotherapy. In advanced gastric cancer patients, both NLR and PLR had significant effects on prognosis, so they may find application as easily measured prognostic factors for such patients.
我们旨在研究基线中性粒细胞、淋巴细胞和血小板计数以及中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）对局部和晚期胃癌患者的预后价值。
在这项回顾性横断面研究中，共纳入了103例胃癌患者。评估了所有患者的特征和总生存期（OS）。记录了全血细胞计数检测的数据，包括中性粒细胞、淋巴细胞、单核细胞、白细胞（WBC）和血小板（Plt）计数、血红蛋白水平（Hb），并在应用任何治疗前，于病理诊断前为每位患者获取NLR和PLR。
在这些患者中，53例患有局部疾病，接受了手术，并在必要时接受了辅助放化疗。其余50例患有晚期疾病，仅接受了化疗。局部胃癌患者组的OS时间为71.6±6个月，晚期胃癌组为15±2个月。单因素分析表明，在局部胃癌患者中，仅高血小板计数（p = 0.013）与较好的OS相关。相比之下，在晚期胃癌患者中，低NLR（p = 0.029）和低PLR（p = 0.012）均与较好的OS相关。
本研究表明，NLR和PLR对接受手术并接受辅助放化疗的局部胃癌患者的预后没有影响。在晚期胃癌患者中，NLR和PLR均对预后有显著影响，因此它们可能作为此类患者易于测量的预后因素而得到应用。
